A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-25. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Multi/minicore myopathy is a congenital myopathy usually caused by mutations in either the SELENON and RYR1 genes. It is characterised the presence of multifocal, well-circumscribed areas with reduction of oxidative staining and low myofibrillar ATPase on muscle biopsy. It is also known as Minicore myopathy, Multicore myopathy, Multiminicore myopathy, Minicore myopathy with external ophthalmoplegia, Multicore myopathy with external ophthalmoplegia and Multiminicore disease with external ophthalmoplegia.
=== Garn: Spacesickness === The garn is NASA's unit of measure for symptoms resulting from space adaptation syndrome, the response of the human body to weightlessness in space, named after US Senator Jake Garn, who became exceptionally spacesick during an orbital flight in 1985. If an astronaut is completely incapacitated by space adaptation syndrome, he or she is under the effect of one garn of symptoms.
=== Australian action === On August 10, 2016, Australian litigation funder IMF Bentham announced an agreement to fund a class action led by the law firm Gadens against the Australian Department of Defence for economic losses to homeowners, fishers, and farmers resulting from the use of aqueous film forming foam (containing PFOA) at RAAF Base Williamtown.
In the above example, the combination of whole rice and canned chickpeas has no limiting amino acids. This means that consuming only rice and chickpeas, in these specific quantities of 306 g/day and 261 g/day respectively, for long periods of time, would easily combine to create complete protein, as it would not result in any of the essential amino acid deficiency. As the data of the example show, all essential amino acids are found in a specific plant. However, one or more of them may be limiting. For this reason, vegan and vegetarian diets need to be varied in terms of plants consumed.
Sources: en.wikipedia.org
Spirulina is the dried biomass of cyanobacteria (blue-green algae) that can be consumed by humans and animals. The three species are Arthrospira platensis, A. fusiformis, and A. maxima. Recent research has further moved all these species to Limnospira. L. fusiformis is also found to be insufficiently different from L. maxima to be its own species. The genus Arthrospira was formerly classified in the genus Spirulina, hence the name. Cultivated worldwide, spirulina is used as a dietary supplement or whole food. It is also used as a feed supplement in the aquaculture, aquarium, and poultry industries.
Dershowitz's campaign to acquit von Bülow was assisted by Jim Cramer and future New York attorney general and governor Eliot Spitzer, who were then Harvard Law School students. Dershowitz and his team focused on the discovery of the bag containing the syringes and insulin. Sunny's family had hired a private investigator to look into her coma. The private investigator, Edwin Lambert (an associate of the Bülows' lawyer Richard Kuh), was told by several family members and a maid that Claus had recently been seen locking a closet in the Newport home that previously was always kept open. The family hired a locksmith to drive to the mansion, with the intention of picking the closet lock to find what the closet contained. They had lied to the locksmith and told him that one of them owned the house. When the three arrived, the locksmith insisted that they try again to find the key, and after some searching, Kuh found a key in von Bülow's desk that unlocked the closet. At this point, according to the three men in the original interviews, the locksmith was paid for the trip and left before the closet was actually opened, although the men would later recant that version and insist that the locksmith was present when they entered the closet. It was in the closet that the main evidence against von Bülow was found. In 1984, the two convictions from the first trial were reversed by the Rhode Island Supreme Court. In 1985, after a second trial, von Bülow was found not guilty on all charges.
It contended that the benefits were substantial and that even if bacteria became resistant, new antibiotics would soon be developed, and there was no evidence that bacterial resistance in animals impacted human health. The Netherthorpe committee's conclusions were undermined by new research even before they were published, and the committee was recalled to reconsider the issue in 1965. New studies had shown that bacteria were not only able to inherit the genes for antibiotic resistance, but they could also communicate them to each other. In 1967, a multiresistant strain of E. coli killed fifteen children in the UK. The use of antibiotics in animals for nontherapeutic use was banned there in 1971. Many other European countries soon followed. When Sweden acceded to the European Union (EU) in 1995, a total ban on antibiotic growth promoters (AGPs) had been in place there for ten years. This would be superseded by more relaxed EU rules unless Sweden could demonstrate scientific evidence in favour of a ban. Two Swedish scientists, Anders Franklin and Christina Greko, and two Danish scientists, Frank Aarestrup and Henrik Wegener, took up the fight. The odds seemed against them but this coincided with the United Kingdom BSE outbreak, which resulted in intense political pressure. In December 1996, the European Parliament's Standing Committee on Health and Welfare voted to ban the use of AGPs. The EU went further and recommended broad restrictions on the use of antibiotics. These regulations were adopted in 2019 and took effect in 2022.
Petrov underwent intense questioning by his superiors about his actions. Initially, he was praised for his decision. General Yuri Votintsev, then commander of the Soviet Air Defense's Missile Defense Units, who was the first to hear Petrov's report of the incident (and the first to reveal it to the public in 1998), stated that Petrov's "correct actions" were "duly noted". Petrov himself stated he was initially praised by Votintsev and was promised a reward, but recalled that he was also reprimanded for improper filing of paperwork with the pretext that he had not described the incident in the military diary. He received no reward. According to Petrov, this was because the incident and other bugs found in the missile detection system embarrassed his superiors and the influential scientists who were responsible for it, so that if he had been officially rewarded, they would have had to be punished. He was reassigned to a less sensitive post, took early retirement (although he emphasized that he was not "forced out" of the army, as is sometimes claimed by Western sources), and suffered a nervous breakdown. Oleg Kalugin, a former KGB chief of foreign counter-intelligence who knew Soviet leader Yuri Andropov well, said that Andropov's distrust of American leaders was profound. It was conceivable that if Petrov had declared the satellite warnings valid, such an erroneous report could have provoked the Soviet leadership into becoming bellicose. Kalugin said: "The danger was in the Soviet leadership thinking, 'The Americans may attack, so we better attack first.'"
FSH is used commonly in infertility therapy, mainly for ovarian hyperstimulation as part of IVF. In some cases, it is used in ovulation induction for reversal of anovulation as well. FSH is available mixed with LH activity in various menotropins including more purified forms of urinary gonadotropins such as Menopur, as well as without LH activity as recombinant FSH (Gonapure, Gonal F, Follistim, Follitropin alpha).
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.